One possible consequence from the assumption is that Teva will win in court and in this case the 'fortune cookie' argument will matter only after 2014. I don't see why Teva should settle before Copaxone's patent expiration date, if they can win the patent lawsuit against NVS. The other problem is we assume Teva will be arguing to the court that NVS’ generic Copaxone is an exact copy while they may only accuse NVS with stealing some Copaxone trade secrets - not all of them.
Market Data 
Markets 
AI
